We are focused
on treating cancer

Impilo is a privately held drug discovery and development company focused on a novel approach to enable nucleic acid-based medicines to effectively treat solid tumor cancers.

The Impilo Platform™ provides a tumor-targeted tissue penetration capability to specifically enhance nucleic acid drug delivery to tumors. Impilo is advancing internal programs and partnering efforts towards the clinic that hold potential to address unmet needs for solid tumor cancer patients.

Our experienced team

The company was founded by scientists and executives with deep experience and commitment to enable cancer patients to benefit from this important emerging drug class.

“Impilo aims at transforming the treatment of solid tumor cancers. The Company’s tumor-targeted, tissue penetrating technology takes advantage of a pathway that is normally utilized for nutrient uptake by tissues, and that tumors shave hijacked to serve their own nutrient needs. By activating this pathway selectively in tumors, we harness it to specifically enhance drug delivery to tumors. Importantly, the pathway is also active in tumor stroma, converting this major impediment to nucleic acid-based drug delivery into a conduit for such drugs’ entry into tumors.”

Erkki Ruoslahti, MD, PhD


David Slack, MBA


John Grundy, PhD

Chief Development Officer

Board of Directors

Erkki Ruoslahti, MD, PhD

Scientific Founder, Board Member and Chairman of the Scientific Advisory Board

David Mazzo, PhD

CEO of Lisata
Therapeutics, Inc.

David Slack, MBA

Impilo CEO

Scientific Advisory Board

Erkki Ruoslahti, MD, PhD

SAB Chairman

Sangeeta Bhatia, MD, PhD

Professor, MIT & HHMI, Director, Marble Center for Cancer Nanomedicine

Kristiina Vuori, MD, PhD

President & CEO, Sanford Laboratories; Professor and former President, Sanford Burnham Prebys Medical Discovery Institute

Michael Sailor, PhD

Distinguished Professor, UCSD, Director, UCSD Institute for Materials Discovery & DesignBurnham Prebys Medical Discovery Institute

Frank Slack, PhD

Director, HMS Initiative for RNA Medicine, Department of Pathology, BIDMC Cancer Center/Harvard Medical School

Kazuki Sugahara, MD, PhD

Physician and scientist at Columbia University College of Physicians and Surgeons

Our Partners
and Investors

Impilo will enter partnerships to access nucleic acid-based drug candidates to high-interest anticancer targets that may be enabled by the Impilo Platform™. The Company will also enter partnerships to apply the Impilo Platform™ to enable partners’ nucleic acid-based drugs a range of therapeutic modalities to effectively treat solid tumor cancers.

Lisata (NASDAQ: LSTA) granted Impilo exclusive rights to iRGD for nucleic acid-based drug applications and assigned rights to other technologies in exchange for equity in Impilo. Lisata also received right of first negotiation for an Impilo-generated drug development candidate.